Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Stanford researchers in the laboratory of Dr. Daria Mochly-Rosen have developed novel small molecules for modulating ALDH2 (mitochondrial aldehyde dehydrogenase-2).